Últimas noticias sobre International Money (NASDAQ:IMXI) Bolsa

IntL Money Express

International Money Express Inc is a processor of money transfer services in the USA to the Latin America and the Caribbean (LAC) corridor. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.

International Money

International Money Express, Inc. - Common Stock

International Money Express Inc

News

SONM

Sonim Technologies Announced The Receipt Of Initial Purchase Orders For The Sonim XP Pro Thermal, Its Latest Innovation In Rugged Mobile Solutions, Ahead Of Its General Availability Later This Quarter

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4415958-1&amp;h=3386947000&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc.">Genprex, Inc.</a> ("Genprex" or the "Company") (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gnpx#NASDAQ">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical data for Reqorsa&#xAE; Gene Therapy (quaratusugene ozeplasmid), for the treatment of KRASG12C mutant non-small cell lung cancer (NSCLC).&nbsp;This data were presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting being held April 25-30, 2025 in Chicago, Illinois.

Penny Stocks

GNPX

Genprex's Gene Therapy Shows Results for Lung Cancer Treatment at AACR Meeting

WIIM

GRMN

Garmin shares are trading lower after the company reported worse-than-expected Q1 earnings.

The transaction includes the acquisition of Jeffs' Brands' wholly-owned subsidiary, Smart Repair Pro, and its approximately 49.1% ownership interest in SciSparc Nutraceutical Inc. by a Canadian public company in exchange for an up to 90% equity interest (on a fully diluted basis) in such company
Tel Aviv, Israel, April 30, 2025 (GLOBE NEWSWIRE) -- Jeffs' Brands Ltd ("Jeffs' Brands" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFBR#NASDAQ">JFBR</a>, JFBRW))), a data-driven e-commerce company operating on the Amazon Marketplace, today announced that it has entered into a definitive agreement ("the Agreement") with Plantify Foods, Inc. (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/PTFY#TSXV">PTFY</a>)&nbsp; a Canadian public company (the "Acquiror") to sell its wholly-owned subsidiary, Smart Repair Pro, which operates Jeffs' Brands' stores on the Amazon U.S. Marketplace and owns Pure NJ Logistics LLC, and its approximately 49.1% ownership interest in SciSparc Nutraceuticals Inc. ("SNI"), which is currently held by its wholly-owned subsidiary, Jeffs' Brands Holdings Inc.
In exchange, Jeffs' Brands is expected to receive up to a 90% equity interest in the Acquiror (on a fully diluted basis), calculated as of immediately following the closing and based on a valuation of CAD 17.125 million (approximately $11.8 million) for Smart Repair Pro and the minority interest in SNI, and a valuation of CAD 4.85 million (taking into account the full potential consideration and contingent on the Acquiror having cash holdings of at least CAD 300,000 (approximately USD $207,000) for the Acquiror (together, the "Transaction").

JFBR

TSXV:PTFY

Jeffs' Brands Agrees With Plantify Foods To Sell Smart Repair Pro For About $11.8M

Trane Technologies shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 GAAP EPS and sales guidance above estimates.

Gibraltar's Board of Directors has approved a new repurchase program of up to an additional $200 million of common stock. This program succeeds the current program, which will end on May 2, 2025, and has a duration of an additional three years, ending April 30, 2028.

Buybacks

ROCK

Gibraltar Extends Stock Repurchase Plan With $200M Investment Over Next Three Years

Gates Industrial Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTES#NYSE">GTES</a>) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.33 by 9.09 percent. This is a 5.88 percent increase over earnings of $0.34 per share from the same period last year. The company reported quarterly sales of $847.60 million which beat the analyst consensus estimate of $822.88 million by 3.00 percent. This is a 1.74 percent decrease over sales of $862.60 million the same period last year.

Earnings

Earnings Beats

GTES

Gates Industrial Corp Q1 Adj. EPS $0.36 Beats $0.33 Estimate, Sales $847.60M Beat $822.88M Estimate

Guidance

EMCOR Group Sees FY2025 Adj EPS $22.65-$24.00 vs $23.18 Est; Affirms FY2025 Sales Guidance of $16.10B-$16.90B vs $16.37B Est

Wells Fargo analyst Ike Boruchow upgrades Levi Strauss (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) from Equal-Weight to Overweight and raises the price target from $17 to $20.

Upgrades

Price Target

Analyst Ratings

LEVI

Wells Fargo Upgrades Levi Strauss to Overweight, Raises Price Target to $20

WeRide Received The District's First Batch Of Driverless Road Testing Licenses, Authorizing Its Robovan W5 For Driverless Testing On Public Roads

Lancaster Colony (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LANC#NASDAQ">LANC</a>) reported quarterly earnings of $1.54 per share which missed the analyst consensus estimate of $1.59 by 3.14 percent. This is a 6.94 percent increase over earnings of $1.44 per share from the same period last year. The company reported quarterly sales of $457.84 million which missed the analyst consensus estimate of $483.92 million by 5.39 percent. This is a 2.89 percent decrease over sales of $471.45 million the same period last year.

Earnings Misses

LANC

Lancaster Colony Q3 Adj. EPS $1.54 Misses $1.59 Estimate, Net sales $457.84M Miss $483.92M Estimate

Gibraltar Industries Affirms FY2025 Adj EPS Guidance of $4.80-$5.05 vs $4.73 Est; Affirms FY2025 Sales Guidance of $1.40B-$1.45B vs $1.43B Est

– Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events by 20% in Overall Study Population Compared to Placebo; Even More Prominent 30% Reduction in High Unmet Need Population of Primary Progressive Multiple Sclerosis –
– Showed Consistent Reduction of Disability Worsening in Subpopulations Without Inflammatory Lesions at Baseline in Overall Study Population; Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events in Patients Without Gadolinium-Enhancing Lesions at Baseline by 29% Compared to Placebo –
– Reduced Annualized Rate of Thalamic Brain Volume Loss by 20% Compared to Placebo –
– Confirmed Favorable Safety and Tolerability Observed in Previous Clinical Trials; No New Safety Signals Identified –
– Webcast to be Held Today, April 30, at 8:00 am ET –
- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4416494-1&amp;h=1233229441&amp;u=https%3A%2F%2Fimux.com%2F&amp;a=Immunic%2C+Inc.">Immunic, Inc.</a>&nbsp;(NASDAQ:<a href="https://www.benzinga.com/stock/IMUX#NASDAQ">IMUX</a>), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced positive data from its phase 2 CALLIPER trial of nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with progressive multiple sclerosis (PMS).
Clinical Endpoints
In the overall PMS patient population (n=467), vidofludimus calcium reduced the relative risk of 24-week confirmed disability worsening (24wCDW) events based on changes in the expanded disability status scale (EDSS) by 20% compared to placebo. Further analyses by disease subtype demonstrated that vidofludimus calcium was associated with a 30% reduction in the relative risk of 24wCDW events in the primary progressive multiple sclerosis (PPMS) study population (n=152) compared to placebo and a respective 15% reduction in the non-active secondary progressive multiple sclerosis (naSPMS) study population (n=268). Reduction of confirmed disability worsening is widely considered to be the most recognized regulatory approval endpoint for registrational studies in progressive forms of multiple sclerosis (MS).
Immunic believes that these reductions in 24wCDW events are remarkable in light of the overwhelming non-activity of the CALLIPER population. In support, the evidence of focal inflammatory disease (gadolinium-enhancing lesions at baseline in 6.8% of naSPMS and 17.8% of PPMS patients) and the number of on-study relapses (5.8% in the overall patient population) are lower than in most historical PMS trials.
A consistent reduction of disability worsening was observed in the different subpopulations with or without inflammatory gadolinium-enhanced lesion activity at baseline and during the study. Vidofludimus calcium reduced the relative risk of 24wCDW events in patients without gadolinium-enhancing lesions at baseline by 29% compared to placebo. In historical studies, such&nbsp;patients were largely shown to not benefit from current anti-inflammatory therapies. Immunic believes the substantial effect in these patients, therefore, underlines the previously observed neuroprotective effect of Nurr1 activation by vidofludimus calcium.

Biotech

General

IMUX

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% In Primary Progressive Multiple Sclerosis Patients From Phase 2 CALLIPER Trial

Silo Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>)&nbsp;on Wednesday released results for its preclinical <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">study evaluating SP-26</a>.
SP-26 is a ketamine-based injectable dissolvable polymer implant for chronic pain and fibromyalgia. If clinically successful, SP-26 could qualify for the FDA's streamlined 505(b)(2) regulatory <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43620172/silo-pharma-announces-positive-initial-pharmacokinetic-safety-and-tolerability-study-of-sp-26-for-" rel="noreferrer noopener">pathway for drug approval</a>.
The study met all endpoints, including survival, clinical observations, body weight stability, neurological assessments, and histopathological evaluation.
The study, which was conducted in minipigs, evaluated the pharmacokinetics, safety, and local tolerability of SP-26 formulations when administered subcutaneously.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44243481/exclusive-alzamend-neuro-to-launch-phase-2-study-for-lead-drug-for-ptsd-patients-in-late-2025-to-" rel="noreferrer noopener">EXCLUSIVE: Alzamend Neuro To Launch Phase 2 Study For Lead Drug For PTSD Patients In Late 2025 To Assess Lithium Delivery Benefits</a>
SP-26 implants are designed to deliver ketamine at a controlled rate, avoiding the dissociative effects associated with IV bolus injection and providing a viable alternative to highly addictive opioid treatments.
"SP-26 has been designed to offer a new approach to pain management by providing sustained, sub-psychedelic levels of ketamine in an abuse-deterrent format," commented Eric Weisblum, CEO of Silo Pharma. "Preclinical SP-26 research overall has focused on ensuring that the safety profile of SP-26 aligns with FDA requirements for potential at-home therapeutic designation.&nbsp;If approved, SP-26 could become the first at-home injectable ketamine-based therapeutic."
Study Highlights:
<ul>
<li>Safety Profile: No implant-related adverse events were observed. To the study conclusion, animals maintained a healthy weight, normal neurological behavior, and full survival.</li>
<li>Sustained Drug Release: Ketamine was steadily released post-implantation, with measurable systemic exposure achieved across all dose levels. Peak drug levels were reached within 1 hour in most subjects, with sustained plasma concentrations observed for up to 22 days.</li>
<li>Minimal Tissue Reaction: Both formulations elicited minimal to mild chronic inflammation at the implant sites, with no dose-dependent or formulation-specific differences.</li>
</ul>
On Monday, Silo Pharma filed a patent application with the U.S. Patent and Trademark Office (USPTO) focused on the neurology drug SPC-14, an intranasal compound for Alzheimer's disease exclusively licensed to Silo <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g45035966/silo-pharma-expands-intellectual-property-portfolio-with-patent-application-for-exclusively-licens" rel="noreferrer noopener">Pharma from Columbia University</a>.&nbsp;
Price Action: SILO stock is up 3.72% at $0.84 during the premarket session at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/04/45087119/analyst-warns-starbucks-faces-growing-risks-from-competition-costs-and-global-tensions" target="_blank" rel="noreferrer noopener">Analyst Warns Starbucks Faces Growing Risks From Competition, Costs, and Global Tensions</a></li>
</ul>

Health Care

Market-Moving Exclusives

Exclusives

SILO

EXCLUSIVE: Silo Pharma's Investigational Ketamine Implant Hits All Endpoints In Pain Study In Animal Models

EMCOR Group Q1 Adj. EPS $5.26 Beats $4.62 Estimate, Sales $3.87B Beat $3.78B Estimate

Public Service Enterprise (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEG#NYSE">PEG</a>) affirms FY2025 Adj EPS guidance from $3.94-$4.06 to $3.94-$4.06 vs $4.01 analyst estimate..

Public Service Enterprise Affirms FY2025 Adj EPS Guidance of $3.94-$4.06 vs $4.01 Est

Hess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HES#NYSE">HES</a>) reported quarterly earnings of $1.81 per share which beat the analyst consensus estimate of $1.61 by 12.42 percent. This is a 42.72 percent decrease over earnings of $3.16 per share from the same period last year. The company reported quarterly sales of $2.94 billion which beat the analyst consensus estimate of $2.71 billion by 8.22 percent. This is a 12.06 percent decrease over sales of $3.34 billion the same period last year.

Hess Q1 Adj. EPS $1.81 Beats $1.61 Estimate, Sales $2.94B Beat $2.71B Estimate

Clean Harbors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLH#NYSE">CLH</a>) reported quarterly earnings of $1.09 per share which missed the analyst consensus estimate of $1.10 by 0.91 percent. This is a 15.5 percent decrease over earnings of $1.29 per share from the same period last year. The company reported quarterly sales of $1.43 billion which missed the analyst consensus estimate of $1.45 billion by 1.66 percent. This is a 3.85 percent increase over sales of $1.38 billion the same period last year.

Clean Harbors Q1 EPS $1.09 Misses $1.10 Estimate, Sales $1.43B Miss $1.45B Estimate

Quoin Pharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) (the "Company" or "Quoin"), a late clinical stage, specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases, today announces that it has received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).
The notification from Nasdaq confirms that for the last 13 consecutive business days, the closing bid price of the Company's ordinary shares was at or above $1.00 per share. Accordingly, Nasdaq considers the matter closed.

QNRX

Quoin Pharma Regains Nasdaq Compliance With Minimum Bid Price Requirement

PPL (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPL#NYSE">PPL</a>) reported quarterly earnings of $0.60 per share which beat the analyst consensus estimate of $0.54 by 11.11 percent. This is a 11.11 percent increase over earnings of $0.54 per share from the same period last year. The company reported quarterly sales of $2.50 billion which beat the analyst consensus estimate of $1.97 billion by 26.86 percent. This is a 8.68 percent increase over sales of $2.30 billion the same period last year.

PPL Q1 Adj. EPS $0.60 Beats $0.54 Estimate, Sales $2.50B Beat $1.97B Estimate

Press Releases

Intermex to Release Third Quarter 2024 Earnings

Intermex Reports Third-Quarter Results

International Money Express, Inc. to Host Investor Day February 26, 2025

International Money Express, Inc. (Intermex) Strengthens Digital Remittance Services with Acquisition of Amigo Paisano's Business

International Money Express, Inc (Intermex) Expands Connectivity: Launches International Top-Up Services Across 130+ Countries

Intermex to Release Fourth Quarter and Full Year 2024 Earnings

Intermex Launches Wire Transfers via WhatsApp, Making Money Transfers Easier Than Ever

Intermex Reports Fourth-Quarter and Full-Year Results

Intermex Empowers Store Owners With Launch of Intermex SOMA: A Game-Changing Mobile App for Business Management on the Go

Comments

International Money

Noticias

Últimas noticias sobre International Money (NASDAQ:IMXI) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL